EMA decides to withdraw the approval of…

medicine Tuesday, 16 July 2024 Amsterdam The farnesoid-X agonist obeticholic acid, which was provisionally approved as Ocaliva for the treatment of primary biliary cholangitis (PBC) at the end of 2016 due to its favorable effects